← Back to patent-cliff list
TQB-3455
Tier C — Watch / tradeTQB-3455
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IDH2
Indications (approved)：Acute myeloid leukaemia, Solid tumour, Haematological malignancy, 神经胶质瘤, Myelodysplastic syndrome
Regional status
US
-
EU
-
China
Phase II
2025-08-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TQB-3455?
Approved indications include: Acute myeloid leukaemia, Solid tumour, Haematological malignancy, 神经胶质瘤, Myelodysplastic syndrome.
When does the TQB-3455 patent expire?
No public expiry year is available for TQB-3455 yet; this page updates once verified.
How do I get a quote for TQB-3455 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30